Losigamone: A putative antiepileptic drug

George L. Morris, Susan Collins, Walter Bell, J. Todd Sahlroot, Margaret Matula, James J. Cereghino

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Losigamone (LSG) has shown anticonvulsant efficacy and low neurotoxicity in preclinical testing and has been tolerated in Phase I clinical trials. We report an open-label, add-on tolerability study of six ascending LSG dosage levels from 600 to 2,100 mg daily in patients receiving phenytoin (PHT), carbamazepine (CBZ), or combination PHT/CBZ. Dosage was escalated weekly, with assessment including reports of adverse events (AE), seizure diary, neurologic and physical examination, electrocardiogram (ECG), and laboratory tests. No serious AE were reported, and those most common AE were headache and dizziness. No significant alteration in PHT, CBZ, or CBZ-epoxide (CBZ-E) levels was noted. No clinically significant change in laboratory tests was noted. A median seizure reduction during LSG treatment as compared with baseline of 39% was achieved during the study. All 9 patients continued into an extension study, and 3 have remained seizure-free for as long as 2 years. Some brief increases in seizure frequency were evident at the 1,800- and 2,100-mg daily dosage levels. We conclude that continued evaluation of LSG for the treatment of partial seizures is indicated.

Original languageEnglish (US)
Pages (from-to)62-66
Number of pages5
JournalJournal of Epilepsy
Issue number2
StatePublished - Mar 4 1997
Externally publishedYes


  • Antiepileptic drugs
  • Controlled clinical trial
  • Drug toxicity
  • Losigamone
  • Partial seizures

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology


Dive into the research topics of 'Losigamone: A putative antiepileptic drug'. Together they form a unique fingerprint.

Cite this